MedTrace Logo

Local Ablative Therapy for Patients With Multiple (4-10) Brain Metastases

NCT04397978 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 180

Last updated 2024-07-01

No results posted yet for this study

Summary

To observe the quality of life (QOL) and to report on toxicity and outcome parameters after the (repeated) use of local ablative therapy (LAT) i.e. stereotactic radiotherapy (SRT) for patients with multiple (4-10) brain metastases

Conditions

  • Brain Metastases, Adult

Interventions

RADIATION

Stereotactic radiotherapy

Local ablative therapy with SRT

Sponsors & Collaborators

  • Universitaire Ziekenhuizen KU Leuven

    lead OTHER

Principal Investigators

  • Patrick Berkovic, MD · UZ Leuven

  • Maarten Lambrecht, PHD · UZ Leuven

  • Eva Oldenburger, MD · UZ Leuven

  • An Nulens · UZ Leuven

  • Lien Smets, BA · UZ Leuven

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-10
Primary Completion
2025-06-01
Completion
2025-06-01

Countries

  • Belgium

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04397978 on ClinicalTrials.gov